PBAC's latest decision on Voriconazole: Recommended with restriction (2014). Considered for Prophylaxis of invasive fungal infections, including yeasts and moulds, in patients at high risk of developing such infections (specifically in AML/MDS patients with anticipated neutropenia, GVHD patients with acute or extensive chronic disease, and high-risk allogeneic haematopoietic stem cell transplant recipients).
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2014
Submissions
1
2014 → 2014
Eligible population
Patients at high risk of invasive fungal infections: (1) acute myeloid leukaemia or high-risk myelodysplastic syndrome patients with anticipated neutropenia (absolute neutrophil count <500 cells/mm³) for ≥10 days receiving chemotherapy; (2) patients with acute GVHD grades II–IV or extensive chronic GVHD receiving intensive immunosuppressive therapy after allogeneic haematopoietic stem cell transplant; (3) high-risk AlloHSCT recipients (cord blood, unrelated donor transplant with bone marrow source, or likely delayed engraftment).
Therapy area
Infectious disease
Line of therapy
First-line
Evidence base
Meta-analysis
Primary endpoint
Incidence of proven or probable invasive fungal infection; all-cause mortality